Wells Fargo
TGTX icon

Wells Fargo’s TG Therapeutics TGTX Stock Holding History

Wells Fargo’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,900
Closed -$104K – 7480
2022
Q1 		$104K Buy
+10,900
New +$126K ﹤0.01% 5313

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo's TGTX Position: Q1 2026 in Review

Wells Fargo reduced its TG Therapeutics (TGTX) stake by 16% in Q1 2026, selling an estimated $1.88M and leaving 332,720 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

Wells Fargo first reported a position in TGTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $11.8M in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Wells Fargo held 332,720 shares of TG Therapeutics worth $11.1M as of Q1 2026.
  • Wells Fargo sold 62,960 TG Therapeutics shares in Q1 2026, an estimated $1.88M.
  • TG Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #1955 holding.
  • Wells Fargo first reported a position in TG Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's TG Therapeutics position peaked at $11.8M in Q4 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.